Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Trastuzumab Emtansine in Chinese HER2+ Breast Cancer
NCT03153163Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Primary endpoints: Area Under the Concentration-Time Curve, Maximum Serum Concentration and 4 more. Started Jun 2017; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03153163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153163.